Myxofibrosarcoma primary cultures: molecular and pharmacological profile
Open Access
- 28 October 2017
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 9 (12), 755-767
- https://doi.org/10.1177/1758834017737472
Abstract
Background: Myxofibrosarcoma (MFS), formerly considered as a myxoid variant of malignant fibrous histiocytoma, is the most common sarcoma of the extremities in adults and is characterized by a high frequency of local recurrence. The clinical behavior of MFS is unpredictable and the efficacy of chemotherapy is still not well documented. Furthermore, given the relatively recent recognition of MFS as a distinct pathologic entity its cellular and molecular biology has still not been extensively studied in patient-derived preclinical models. We examined the molecular biology and treatment outcomes of high-grade, patient-derived MFS primary cultures.Methods: A total of three patient-derived MFS primary cultures were analyzed. We evaluated the role of CD109 expression and also looked for a correlation between transforming growth factor-beta (TGF-β) expression and sensitivity of the primary cultures to different drugs.Results: CD109 was a promising marker for the identification of more aggressive high-grade MFS and a potential therapeutic target. The results also highlighted the potential role of TGF-β in chemoresistance. Pharmacological analysis confirmed the sensitivity of the cultures to chemotherapy. The most active treatments were epirubicin alone and epirubicin in combination with ifosfamide, the latter representing the current standard of care for soft tissue sarcomas (STSs), including MFS.Conclusions: Our results provide a starting point for further research aimed at improving the management of MFS patients undergoing chemotherapy.Keywords
This publication has 58 references indexed in Scilit:
- TGF-β inhibition enhances chemotherapy action against triple-negative breast cancerJCI Insight, 2013
- Prognostic Factors and Outcomes of Patients with MyxofibrosarcomaAnnals of Surgical Oncology, 2012
- The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptorsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Processing of CD109 by furin and its role in the regulation of TGF-β signalingOncogene, 2010
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different SchedulesJournal of Clinical Oncology, 2009
- Up‐regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavityCancer Science, 2008
- Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasmsLaboratory Investigation, 2008
- CD109 expression in basal‐like breast carcinomaPathology International, 2008
- Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesotheliomaCancer Science, 2008
- CD109 expression in squamous cell carcinoma of the uterine cervixPathology International, 2005